Healthcare / Medical DevicesMilan
$9.34
+0.26 (+2.86%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-1.5M · quality 37.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$49M
P/E
7.2x
↓EV/EBITDA
5.4x
↓ROE
10.0%
↑Gross Margin
39.6%
↓Debt/Equity
1.16
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+12.5%
FCF CAGR
—
FCF margin
-4.0%
FCF / Net income
-0.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $141.5M · net income $6.8M · FCF $-5.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $141.5M | $141.5M | $122.3M | $121.6M | $99.5M |
| Net Income | $6.8M | $6.8M | $5.9M | $5.1M | $3.6M |
| EBITDA | $19.1M | $19.1M | $17.6M | $15.6M | $11.3M |
| EPS | — | — | — | 0.96 | 0.66 |
| Gross Margin | 39.6% | 39.6% | 39.8% | 39.2% | 41.7% |
| Operating Margin | 9.2% | 9.2% | 8.6% | 8.0% | 7.8% |
| Net Margin | 4.8% | 4.8% | 4.8% | 4.2% | 3.6% |
| Balance Sheet | |||||
| Debt/Equity | 1.16 | 1.16 | 1.07 | 1.15 | 1.01 |
| Current Ratio | 1.82 | 1.82 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-5.7M | $-5.7M | $-991018.00 | $-1.5M | $10941.00 |
| Returns | |||||
| ROE | 10.0% | 10.0% | 9.4% | 8.7% | 6.5% |
| Valuation | |||||
| P/E | 7.24 | 7.24 | — | 8.40 | 15.33 |
| EV/EBITDA | 5.42 | 5.42 | 4.05 | 4.89 | 7.79 |
| P/B | 0.73 | 0.73 | 0.60 | 0.73 | 1.00 |
| Growth & Yield | |||||
| Revenue Growth | 15.7% | 15.7% | 0.5% | 22.2% | — |
| EPS Growth | — | — | — | 45.2% | — |
| Dividend Yield | 2.2% | 2.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.2%
Start / end P/E
n/dx → n/dx
EPS bridge
n/d → n/d
Residual
+12.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.